PAREXEL International Corp. has signed a definitive agreement to acquire privately-owned Quantum Solutions India (QSI), a provider of specialized pharmacovigilance services based in Chandigarh. Financial terms were not disclosed. The acquisition is expected to close in early April, subject to customary closing conditions.
 
QSI was established in 2004, and provides a range of pharmacovigilance services, including individual case safety report processing, brand physician activities, affiliate support, aggregate report writing, literature reviews, and signal detection. The company has approximately 900 employees and services customers globally.
 
The QSI business will be integrated into PAREXEL’s Peri/Post-Approval Services group, which is part of the CRS segment, and is expected to contribute to PAREXEL’s Regulatory Outsourcing Services business within the Consulting segment.
 
Josef von Rickenbach, chairman and chief executive officer of PAREXEL said, “The acquisition of QSI will strengthen our capabilities in the growing field of outsourced safety management solutions, or pharmacovigilance. It will help us to create greater scale in this service area, and thereby enable us to provide a more comprehensive, efficient, and economical solution to clients around the world. Combined with the existing post-approval and regulatory strengths of PAREXEL, this acquisition will support the expansion of our pharmacovigilance services onto a broader platform. We are excited to be able to offer our clients QSI’s leading services through our Clinical Research Services business.”